Abstract. Germ line mutations in the tumor suppressor adenomatous polyposis coli (APC) gene, predispose for the clinical familial adenomatous polyposis (FAP) syndrome, a high risk precursor for early onset colon cancer. Similar mutations in the murine homolog of the APC gene, however, produce adenomas predominantly in the small intestine, rather than in the colon. The objectives of the present study were: i) to develop a preclinical cell culture model for human FAP syndrome and ii) to validate this model as a rapid mechanism-based approach for evaluation of the preventive efficacy of combinations of synthetic pharmacological agents or naturally-occurring phytochemicals, for the risk of colon carcinogenesis. The clonally selected 850Min COL-Cl1 cell line derived from histologically normal colon of ApcMin/+ mouse exhibited aberrant proliferation (64.7% decrease in population doubling time, 820% increase in saturation density, and 81.4% decrease in spontaneous apoptosis), relative to that observed in the colon epithelial cell line C57 COL established from Apc[+/-] C57BL/6J mouse. In addition, unlike the Apc[+/-] C57 COL cells, the Apc mutant cells exhibited enhanced risk for spontaneous carcinogenic transformation as evidenced by 100% increase in anchorage-independent colony formation (C57 COL: 0/12; 850Min COL-Cl1: 12/12, mean colony number 23.6±2.7). Treatment of Apc mutant cells with low dose combination of select mechanistically distinct synthetic chemopreventive agents such as celecoxib (CLX) + difluoro methylornithine (DFMO), or naturally-occurring epigallocatechin gallate (EGCG) + curcumin (CUR) produced 160-400% and 220-430% decrease in the viable cell number respectively, relative to these agents used independently. Furthermore, relative to independent agents, CLX+DFMO and EGCG+CUR combinations produced 31.5-82.1% and 45.9-105.4% greater reduction in the number of anchorage-independent colonies. Thus, aberrant proliferation and increased risk for carcinogenesis in the Apc mutant cells, and their susceptibility to low dose combinations of mechanistically distinct chemopreventive agents validate a rapid approach to prioritize efficacious combinations for long-term animal studies and future clinical trials on prevention of colon cancer.

Introduction

Colon cancer is one of the major causes of morbidity and mortality in the US population, exhibiting a 21% cancer incidence (new cancer cases) and a 15% mortality (cancer-related deaths) in 2006 (1). Stringently optimized specific and sensitive molecular/genetic biomarker assays continue to facilitate early diagnosis and better identification of cancer risk (2-4). However, patient response to traditional chemotherapy remains essentially unaltered, and is associated with adverse side-effects affecting compliance (4). Overall, these aspects emphasize a need for development of reliable models wherein new preventive/therapeutic modalities can be rapidly tested for safety, specificity and efficacy, and for their rational prioritization for subsequent animal experiments and future clinical trials.

In the multi-step process of familial colon carcinogenesis, germ line mutations in the tumor suppressor adenomatous polyposis coli (APC) gene represent the early occurring primary genetic defect. At the clinical level, this early occurring genetic defect characterizes the familial adenomatous polyposis (FAP) syndrome, a precursor for early onset familial colon cancer. It is noteworthy that somatic mutations in APC, together with those in ras, p53, β-catenin or TGF-ß receptor genes are also detectable in familial, hereditary and sporadic colon cancer (5,6).

The ApcMin/+ mutant mouse model represents one of the most widely accepted preclinical animal models for colon cancer. This genetic model however, exhibits spontaneous carcinogenesis, predominantly in the small intestine, rather than in the colon, while the FAP syndrome predisposes for the early onset colon cancer (5-8). Recent evidence, however, has demonstrated that morphologically normal colonic tissue from the ApcMin/+ mutant mouse exhibits up-regulated
expression of genes associated with Apc/β-catenin, NFκB and cell cycle regulatory pathways preceding the appearance of preneoplastic or neoplastic lesions (9,10), suggesting a correlation of perturbed mechanistic biomarkers with an increased risk for carcinogenesis.

The Apc\(^{min/+}\) model has also been extensively utilized to evaluate preclinical efficacy of several mechanistically distinct synthetic pharmacological agents either independently or in combination (9). Low dose combinations of specific enzyme inhibitors, growth factor receptor antagonists, or pleiotropic naturally occurring phytochemicals exhibit enhanced preventive efficacy relative to that observed with these agents used independently (2,3,9). Combinatorial intervention by the use of low dose combinations of synthetic pharmacological agents and/or naturally occurring phytochemicals may lead to reduced toxicity in favor of enhanced efficacy.

Reliable cell culture models expressing clinically relevant genetic defect at the appropriate target organ site and exhibiting quantifiable biomarkers for risk of spontaneous carcinogenesis, represent a novel paradigm as an alternative approach to facilitate rapid mechanism-based prioritization of efficacious chemopreventive agents (11-16). These compounds can be further tested through subsequent animal experiments and future clinical trials for prevention of colon cancer.

Previously optimized methodology to establish long-term subculturable colon epithelial cell lines from Apc [+/+ ] and Apc 1638N [+/-] mice (11,12), has been utilized in the present study to demonstrate that the colon epithelial cell line derived from the Apc\(^{min/+}\) mouse is aberrantly proliferative and is at a higher risk for spontaneous carcinogenic transformation. Furthermore, the Apc mutant cells are susceptible to growth inhibition by combinations of mechanistically distinct synthetic pharmacological agents or naturally occurring phytochemicals. Thus, the data from this study validate a new preclinical cell culture model for early onset familial colon cancer as a mechanistic screen for the efficacy of combination of mechanistically distinct chemopreventive agents.

Materials and methods

**Cell lines.** The wild-type Apc [+/+] C57 COL cell line (source: descending colon of C57BL/6J mouse) and the mutant Apc 850\(^{min/+}\) COL-Cl1 cell line (source: descending colon of ApcMin/ + mouse) were cultured in DME/F12 medium similar to that used for the C57 COL cell cultures. The cell culture model for early onset familial colon cancer as a mechanistic screen for the efficacy of combination of mechanistically distinct chemopreventive agents.

**Materials and methods**

**Cell lines.** The wild-type Apc [+/+] C57 COL cell line (source: descending colon of C57BL/6J mouse) and the mutant Apc 850\(^{min/+}\) COL-Cl1 cell line (source: descending colon of Apc\(^{min/+}\) + mouse) were cultured in DME/F12 medium supplemented with heat inactivated 10% fetal calf serum, 0.24 IU/ml (10 µg/ml) insulin and 1 µM dexamethasone. This culture medium also contained the antibiotic mixture (100 IU/100 µg/ml penicillin/streptomycin + 50 µg/ml fungizone + 50 µg/ml gentamycin). Routinely, the stock cultures were maintained at 37°C in a humidified atmosphere of 95% air: 5% CO₂, fed with fresh medium every 48 h, and were subcultured at 1:10 split at 70-80% confluency (11,12). The Apc mutant 850\(^{min/+}\) COL-Cl1 cell line was clonally selected from a single anchorage-independent colony formed in 0.33% agar. This colony was dissociated and expanded as adherent culture in the DME/F12 medium similar to that used for the C57 COL cells.

**Population doubling time and saturation density.** The population doubling time was calculated from the viable cell counts obtained at 24, 48, 72, 96 and 120 h post-seeding of 1.0x10⁵ cells. These time points represent the duration of the exponential growth phase of the cell lines and are used to determine the population doubling time. The saturation density was determined from the total viable cell counts at the end of day 5 post-seeding of 1.0x10⁵ cells.

**Cell cycle progression.** The cell cycle analysis was performed by determining flow cytometry-based percent distribution of propidium iodide-stained cells in the G0/G1, S, G2/M and sub G0 phases of the cell cycle. Briefly, trypsinized cell suspensions, after appropriate fixation and processing, were scanned on the Epic-752 flow cytometer equipped with a 488 nM excitation and a 630 nM long pass filter. The data from the cell cycle phase distribution were analyzed using the multi-cycle software (11,13). The data obtained from at least 10⁶ fluorescent events were also expressed as G0/G1 : S+G2/M and S+G2/M : subG0 ratios to correlate the status of cell proliferation and cellular apoptosis.

**Anchorage-independent colony formation (AICF).** For this assay, cells suspended in 0.33% agar at an initial density of 100 cells/well were overlaid on a basement layer of 0.6% agar in six-well cluster plates. The cultures were maintained at 37°C, and number of anchorage-independent colonies was determined at day 14 post-seeding.

**Chemopreventive agents.** Selective COX-2 inhibitor celecoxib (CLX), selective ornithine decarboxylase inhibitor difluoro methylornithine (DFMO), and the naturally occurring phytochemicals epigallocatechin gallate (EGCG) and curcumin (CUR) were selected as test compounds based on their documented efficacy in the Apc\(^{min/+}\) mouse model (9,19,20,22-25,28), and their inclusion in several clinical trials (26,27,29,30). The test compounds, obtained from Sigma Chemical Co., St. Louis, MO, were dissolved in 100% ethanol (EtOH) to prepare a 100 mM stock solution. These stock solutions were serially diluted in the culture medium to obtain 5 log concentrations of 0.01, 0.1, 1, 10 and 100 µM for the dose response experiments.

**Table I. Aberrant proliferation in Apc mutant colon epithelial cell line.**

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Cell line</th>
<th>Population doubling time (h)</th>
<th>Viable cell number (x10⁵)</th>
<th>Anchorage-independent colonies</th>
<th>Incidence</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>C57 COL</td>
<td>34</td>
<td>7.4±0.8</td>
<td>0/12</td>
<td>12/12</td>
<td>23.6±2.7</td>
</tr>
<tr>
<td></td>
<td>850(^{min/+}) COL-Cl1</td>
<td>12</td>
<td>67.9±4.6</td>
<td>12/12</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Determined from the exponential growth phase. ** Determined at day 5 post-seeding of 1.0x10⁵ cells. *** Determined at day 14 post-seeding of 100 cells per well in 0.33% agar.
Table II. Aberrant cell cycle progression in Apc mutant colon epithelial cell line.

<table>
<thead>
<tr>
<th>Cell line</th>
<th>( G_0/G_1 ) (Q)</th>
<th>( S+G_2/M ) (P)</th>
<th>Sub ( G_0 ) (A)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C57 COL</td>
<td>75.4±1.6(^{b})</td>
<td>24.8±3.3(^{b})</td>
<td>4.3±1.1(^{f})</td>
</tr>
<tr>
<td>850(^{min}) COL-Cl(_1)</td>
<td>21.8±0.5(^{c})</td>
<td>78.2±2.0(^{c})</td>
<td>0.8±0.5(^{e})</td>
</tr>
</tbody>
</table>

\(^{a}\)Flow cytometry data generated from 10\(^6\) fluorescent events. Mean ± SD, \( n=6 \) per cell line. Q, quiescent; P, proliferative; A, apoptotic; \(^{b,e}\) \( p<0.001 \).

**Results**

**Aberrant proliferation and risk for carcinogenic transformation.** The status of aberrant proliferation and the risk for carcinogenic transformation was evaluated in the Apc \(+/+\) C57 COL and the Apc mutant 850\(^{min}\) COL-Cl\(_1\) cells by determining population doubling time (PDT), viable cell number representing saturation density, and anchorage-independent colony formation (AICF). Relative to C57 COL cells, the Apc mutant 850\(^{min}\) COL-Cl\(_1\) cells exhibited a 64.7% decrease in PDT and an 820% increase in the total viable cell number at day 5 post-seeding. Furthermore, the C57 COL cells lacked AICF (0/12), whereas, the Apc mutant cells exhibited a 100% incidence (12/12), with a mean colony number of 23.6±2.7 (Table I).

The aberrant proliferation exhibited a correlation with altered cell cycle progression. Thus, relative to the C57 COL cells, the Apc mutant cells exhibited a 71.1% decrease in \( G_0/G_1 \) population, a 217% increase in \( S+G_2/M \) population and an 820% decrease in sub \( G_0 \) apoptotic population (Table II). These alterations in the cell cycle progression resulted in a 9.3-fold decrease in \( Q (G_0/G_1) \) : \( P (S+G_2/M) \) ratio, and a 15.9-fold increase in \( P (S+G_2/M) \) : \( A (sub G_0) \) ratio. Thus, these data taken together suggest that aberrantly proliferative Apc mutant cells also have down-regulated cellular apoptosis.

**Susceptibility to chemopreventive agents.** The susceptibility of Apc mutant cells to growth inhibitory effects of CLX, DFMO, EGCG and CUR, the Apc mutant cells were seeded at the initial seeding density of 1.0x10\(^5\) cells in T-25 flasks. After an attachment period of 24 h, the cultures were continuously treated with 5 log \( \mu M \) concentrations of individual agents for the duration of the exponential growth phase. The cultures were fed with fresh medium containing the test compounds every 48 h and cell counts of viable cells were obtained at day 5 post-seeding. Control cultures in parallel were treated with 0.1% EtOH (solvent controls), comparable to that present in 100 \( \mu M \) media. The primary cell count data were converted to inhibitory concentration (IC) range and expressed as IC\(_{50}\) values.

**Dose response of chemopreventive agents.** To evaluate the growth inhibitory effects of CLX, DFMO, EGCG and CUR, the initial seeding density of 1.0x10\(^5\) cells in T-25 flasks. After an attachment period of 24 h, the cultures were continuously treated with 5 log \( \mu M \) concentrations of individual agents for the duration of the exponential growth phase. The cultures were fed with fresh medium containing the test compounds every 48 h and cell counts of viable cells were obtained at day 5 post-seeding. Control cultures in parallel were treated with 0.1% EtOH (solvent controls), comparable to that present in 100 \( \mu M \) media. The primary cell count data were converted to inhibitory concentration (IC) range and expressed as IC\(_{50}\) values.

**Table III. In vivo pharmacokinetics and in vitro dose response of chemopreventive agents on Apc mutant colon epithelial cell line.**

<table>
<thead>
<tr>
<th>Agent</th>
<th>Apc(^{min/+}) plasma levels (( \mu M ))</th>
<th>Inhibitory concentration (( \mu M ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLX(^{c})</td>
<td>2.0-6.0</td>
<td>8.1±0.4</td>
</tr>
<tr>
<td>DFMO(^{d})</td>
<td>86-225</td>
<td>35.1±0.4</td>
</tr>
<tr>
<td>EGCG(^{b})</td>
<td>0.3-2.0</td>
<td>0.7±0.1</td>
</tr>
<tr>
<td>CUR(^{e})</td>
<td>0.8-2.5</td>
<td>29.6±0.4</td>
</tr>
</tbody>
</table>

\(^{c,d,e}\) Extrapolated from a 5 log dose range (0.01-100 \( \mu M \)) at day 5 post-seeding of 1.0x10\(^5\) cells. \(^{b}\) \( p<0.001 \).

**Discussion**

The Apc\(^{Min/+}\) mouse, because of a germ line mutation in codon 850 of the Apc gene, exhibits a high incidence of spontaneous adenomas in the small intestine and represents a genetic preclinical model for clinical colon cancer (5-9). However, unlike that in clinical FAP patients, the colonic segments of the Min mouse exhibit low incidence of adenoma and carcinoma (5,7,8). It is noteworthy that colon carcinogenesis is experimentally induced in the Min mouse model. Thus,
administration of the chemical carcinogen azoxymethane (18), and of the PPAR-γ agonist troglitazone (19,20) results in a high incidence of colonic adenoma and adenocarcinoma. Additionally, genetic modulation such as that in Apc<sup>Min/BubR1</sup> double mutants (21), Smad-3 mutants (45) and Apc<sup>Min/+Smad-3<sup>-/-</sup></sup> double mutants (46) results in accelerated carcinogenesis in the colon. These observations taken together provide evidence for a stronger clinical relevance for the present model of FAP syndrome. Comparative genomic (10) and proteomic (40) data on non-involved colonic mucosal epithelium and adenomatous polyps have demonstrated that the target tissue at risk exhibits distinct gene/protein expression profiles well before the advent of pathogenic changes associated with tumorigenesis, and that these early-occurring molecular alterations are similar to those in adenomas. These data suggest that distinct expression profiles may identify better indicators of carcinogenic risk.

Availability of reliable cell culture models expressing clinically relevant genetic defect (APC mutation) at the appropriate target organ site (colon) with quantifiable biomarkers of risk for carcinogenic transformation (11,12), may eliminate the limitations of the in vivo models, and therefore, represent a valuable complementary approach to long-term animal studies.

The present study demonstrates that the 850<sup>Min</sup> COL-Cl<sub>i</sub> cells originated from morphologically normal descending colon of the Apc<sup>Min/+</sup> mouse are aberrantly proliferative as evidenced by shorter PDT, higher saturation density, higher number of cells in the S+G2/M phase of the cell cycle, and decreased cellular apoptosis. These Apc mutant cells also exhibit higher risk for spontaneous carcinogenic transformation as evidenced by high incidence and frequency of AICF. Consistent with these observations, previous studies have shown that mammary epithelial cells independently transfected with Ras (15), myc (16) or HER-2/neu (17) oncogenes also exhibit aberrant proliferation that is associated with accelerated cell cycle progression and down-regulated cellular apoptosis. Furthermore, these oncogene expressing cells exhibit high incidence of AICF in vitro preceding carcinogenesis upon in vivo transplantation. Thus, AICF represents a sensitive and specific in vitro surrogate end-point biomarker for in vivo carcinogenic transformation. Non-involved colonic tissue from Apc<sup>Min/+</sup> mouse has been demonstrated to exhibit up-regulation of genes associated with the Apc/β-catenin, NFκB pathways and with cell cycle progression (10). These observations together with the phenomenological data from the present study provide a strong rationale to examine whether aberrantly proliferative preneoplastic 850<sup>Min</sup> COL-Cl<sub>i</sub> also exhibit up-regulated expression of molecular targets that are associated with the risk for carcinogenesis.

The Apc<sup>Min/+</sup> mouse model has been used for preclinical efficacy of several pharmacological as well as naturally occurring chemopreventive compounds as single agents that include synthetic NSAIDs (22), selective COX-2 inhibitors (23-25), selective inhibitors of polyamine biosynthetic pathway (26,44), selective antagonists of growth factor receptor function (27), and several naturally-occurring phytochemicals (9,28). Long-term administration of these synthetic pharmacological agents at high doses is associated with systemic toxicity (2-4,29,30). In addition, recent preclinical evidence has shown that long-term administration of the selective COX-2 inhibitor CLX is associated with recurrence of intestinal adenomas in the Apc<sup>Min</sup> mouse model (38). Enhanced efficacy of low dose combinations of several mechanistically distinct synthetic pharmacological agents such as piroxicam + difluro methylornithine (31), sulindac + EGFR antagonist (32), and atorvastatin + CLX (39) has been demonstrated in vivo in the Apc<sup>Min</sup> mouse model. In addition to the combinations of synthetic pharmacological agents, several mechanistically distinct natural phytochemicals have been reported to enhance the efficacy of conventional chemotherapy, leading to a reduction in toxicity (33,41-44). Consistent with these observations, low dose combinations of CLX+DFMO and EGCG+CUR have demonstrated higher efficacy in the present preclinical cell culture model for FAP syndrome, emphasizing the validity of this model.

The ability of combination of mechanistically distinct CLX+DFMO or EGCG+CUR to affect the growth of aberrantly proliferative Apc mutant 850<sup>Min</sup> COL-Cl<sub>i</sub> cells now facilitates rational studies designed to examine the modulation of relevant molecular targets such as cell cycle

### Table IV. Efficacy of chemopreventive agents for growth inhibition of Apc mutant colon epithelial cells.

<table>
<thead>
<tr>
<th>Agent</th>
<th>Concentration</th>
<th>Viable cells&lt;sup&gt;a&lt;/sup&gt; (x10&lt;sup&gt;5&lt;/sup&gt;)</th>
<th>Inhibition (%)</th>
<th>Number of colonies&lt;sup&gt;b&lt;/sup&gt;</th>
<th>Inhibition (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EtOH</td>
<td>0.01%</td>
<td>65.3±4.6&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-</td>
<td>27.0±3.2&lt;sup&gt;d&lt;/sup&gt;</td>
<td>-</td>
</tr>
<tr>
<td>CLX</td>
<td>1 μM</td>
<td>60.8±4.3</td>
<td>6.9</td>
<td>14.8±3.2</td>
<td>45.2</td>
</tr>
<tr>
<td>DFMO</td>
<td>10 μM</td>
<td>56.6±2.8</td>
<td>13.3</td>
<td>10.1±1.2</td>
<td>62.6</td>
</tr>
<tr>
<td>CLX+DFMO</td>
<td>1+10 μM</td>
<td>43.1±3.0&lt;sup&gt;d&lt;/sup&gt;</td>
<td>33.9</td>
<td>4.8±0.6&lt;sup&gt;e&lt;/sup&gt;</td>
<td>82.2</td>
</tr>
<tr>
<td>EGCG</td>
<td>0.1 μM</td>
<td>58.7±4.1</td>
<td>10.1</td>
<td>16.0±1.9</td>
<td>40.7</td>
</tr>
<tr>
<td>CUR</td>
<td>10 μM</td>
<td>54.5±3.8</td>
<td>16.5</td>
<td>11.5±1.4</td>
<td>57.4</td>
</tr>
<tr>
<td>EGCG+CUR</td>
<td>0.1+10 μM</td>
<td>30.5±2.1&lt;sup&gt;d&lt;/sup&gt;</td>
<td>53.3</td>
<td>4.4±0.5&lt;sup&gt;e&lt;/sup&gt;</td>
<td>83.7</td>
</tr>
</tbody>
</table>

<sup>a</sup>Determined at day 5 post-seeding of 1.0x10<sup>5</sup> cells. Mean ± SD, n=6 per treatment group. <sup>b</sup>Determined at day 14 post-seeding of 100 cells per well. Mean ± SD, n=12 per treatment group. c-d, p=0.01, e-gp=0.005.
regulatory proteins and Apc/B-catenin mitogenic signal transduction cascade. In addition, the present model facilitates future studies focused on specific targets that are known to be responsible for preventive efficacy such as COX-2 for CLX (23-25), ornithine decarboxylase for DMFO (26,31), EGF receptor signaling and generation of reactive oxygen species for EGGC (34-36), and NFκB signaling for CUR (37).

In conclusion, the present cell culture model exhibiting quantifiable risk for carcinogenic transformation provides a rapid mechanism-based approach for rational prioritization of effective combinatorial interventions in long-term animal studies and future clinical trials on prevention of colon cancer.

Acknowledgements

We thank Milan Zvanovec and Tonye Briggs for their excellent technical assistance. This research has been supported in part by NIH grants CA 29502-S1 and CA 75029-63 (N.T.) and CA 29502-20 and CA 122394 (M.K.), and funds from The Irving Weinstein Foundation (N.T. and M.K.).

References


